BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16723257)

  • 1. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes.
    Upshaw JL; Leibson PJ
    Semin Immunol; 2006 Jun; 18(3):167-75. PubMed ID: 16723257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
    Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
    Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
    André P; Castriconi R; Espéli M; Anfossi N; Juarez T; Hue S; Conway H; Romagné F; Dondero A; Nanni M; Caillat-Zucman S; Raulet DH; Bottino C; Vivier E; Moretta A; Paul P
    Eur J Immunol; 2004 Apr; 34(4):961-71. PubMed ID: 15048706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NKG2D receptor: sensing stressed cells.
    López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
    Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions.
    Allez M; Tieng V; Nakazawa A; Treton X; Pacault V; Dulphy N; Caillat-Zucman S; Paul P; Gornet JM; Douay C; Ravet S; Tamouza R; Charron D; Lémann M; Mayer L; Toubert A
    Gastroenterology; 2007 Jun; 132(7):2346-58. PubMed ID: 17570210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway.
    Horng T; Bezbradica JS; Medzhitov R
    Nat Immunol; 2007 Dec; 8(12):1345-52. PubMed ID: 17952078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Versatile signaling through NKG2D.
    Long EO
    Nat Immunol; 2002 Dec; 3(12):1119-20. PubMed ID: 12447364
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D.
    Diefenbach A; Tomasello E; Lucas M; Jamieson AM; Hsia JK; Vivier E; Raulet DH
    Nat Immunol; 2002 Dec; 3(12):1142-9. PubMed ID: 12426565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell signaling pathways.
    Vivier E; Nunès JA; Vély F
    Science; 2004 Nov; 306(5701):1517-9. PubMed ID: 15567854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.
    Sáez-Borderías A; Gumá M; Angulo A; Bellosillo B; Pende D; López-Botet M
    Eur J Immunol; 2006 Dec; 36(12):3198-206. PubMed ID: 17109473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKG2D and cytotoxic effector function in tumor immune surveillance.
    Hayakawa Y; Smyth MJ
    Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKG2D ligands: key targets of the immune response.
    González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
    Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells.
    Poggi A; Prevosto C; Zancolli M; Canevali P; Musso A; Zocchi MR
    Ann N Y Acad Sci; 2007 Aug; 1109():47-57. PubMed ID: 17785290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
    Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
    Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
    Ito Y; Kanai T; Totsuka T; Okamoto R; Tsuchiya K; Nemoto Y; Yoshioka A; Tomita T; Nagaishi T; Sakamoto N; Sakanishi T; Okumura K; Yagita H; Watanabe M
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G199-207. PubMed ID: 17962357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
    Wang E; Selleri S; Marincola FM
    Clin Cancer Res; 2007 Dec; 13(24):7228-31. PubMed ID: 18094399
    [No Abstract]   [Full Text] [Related]  

  • 19. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY; Mei JZ; Yao KT
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.